Major Japanese Photo Firm Plans Toyama Buy To Enter Drug Market
This article was originally published in PharmAsia News
Executive Summary
Fujifilm Holdings plans to acquire Toyama Chemical to make the Japanese pharmaceutical company its first major venture into the drug industry. Fujifilm sees the acquisition worth $9.2 billion in annual sales in 10 years, triple current Fujifilm sales. Fujifilm's president said his company plans other mergers and acquisitions in the medical business to replace the photography business, which has been changed by digital cameras. The Toyama takeover is the latest of a string of 20 takeovers under company president Shigetaka Komori. (Click here for more - a subscription may be required
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.